Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epcoritamab +/- Lenalidomide in First-line Anthracycline-ineligible DLBCL
NCT05660967Phase 2Terminated
- Sponsor
- Genmab
- Start
- Mar 2023
- Primary completion
- Jun 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Recombinant Proteins and Enzymes
- Countries
- 12
01
Overview
A Phase 2 trial of epcoritamab in diffuse large B-cell lymphoma (DLBCL), sponsored by Genmab. Started Mar 2023; status: terminated.
02
Drugs
epcoritamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05660967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05660967.